These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2523112

  • 1. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
    Vaessen LM, Kreeftenberg JG, Heyse P, Leerling MF, Baumgartner D, Hendriks GF, Jutte NH, Weimer W.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
    [No Abstract] [Full Text] [Related]

  • 2. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B, Schwinzer R, Wonigeit K, Pichlmayr R.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract] [Full Text] [Related]

  • 3. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract] [Full Text] [Related]

  • 4. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ.
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [Abstract] [Full Text] [Related]

  • 5. Quality control of anti human CD3 and CD4 monoclonal antibodies.
    Leerling MF, Vaessen LM, Reubsaet CH, Weimar W, Ettekoven H, Marsman FR, Kreeftenberg JG.
    Dev Biol Stand; 1990 Dec; 71():191-200. PubMed ID: 2144833
    [Abstract] [Full Text] [Related]

  • 6. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
    Shield CF, Hughes JD, Marlett P, Norman DJ.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
    [No Abstract] [Full Text] [Related]

  • 7. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M, Depierreux M, Florquin S, Najdovski T, Vandenabeele P, Abramowicz D, Leo O, Deschodt-Lanckman M, Goldman M.
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract] [Full Text] [Related]

  • 8. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA, Hoitsma AJ, Tax WJ, Koene RA.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract] [Full Text] [Related]

  • 9. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R, Bluestone JA, Bare CV, Gress RE.
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the immunoregulatory capacity of anti-alpha/beta-TCR and anti-CD3 monoclonal antibodies.
    Kurrle R, Schorlemmer HU, Shearman C, Lauffer L, Frank K, Kanzy EJ, Seiler FR.
    Transplant Proc; 1991 Feb; 23(1 Pt 1):272-6. PubMed ID: 1824982
    [No Abstract] [Full Text] [Related]

  • 11. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
    Hirsch R, Chatenoud L, Gress RE, Bach JF, Sachs DH, Bluestone JA.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1015-6. PubMed ID: 2523111
    [No Abstract] [Full Text] [Related]

  • 12. In vivo immunosuppressive effects of monoclonal antibodies specific for CD3+, CD4+, CD8+, and MHC class II positive cells.
    Stevens HP, Roche N, Hovius SE, Jonker M.
    Transplant Proc; 1990 Aug; 22(4):1783-4. PubMed ID: 2143861
    [No Abstract] [Full Text] [Related]

  • 13. Dose-dependent activation of murine T cells following in vivo administration of anti-murine CD3.
    Ellenhorn JD, Hirsch R, Hartley JP, Bluestone JA.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1013-4. PubMed ID: 2523110
    [No Abstract] [Full Text] [Related]

  • 14. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
    Carreno M, Miller J, Esquenazi V, Milgrom M, Roth D, Fuller L.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
    [No Abstract] [Full Text] [Related]

  • 15. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
    Sherburne CG, Onyekaba CO, Condie RM.
    Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
    [No Abstract] [Full Text] [Related]

  • 16. In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody.
    Ferran C, Bluestone J, Bach JF, Chatenoud L.
    Transplant Proc; 1990 Aug; 22(4):1922-3. PubMed ID: 2143865
    [No Abstract] [Full Text] [Related]

  • 17. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
    Ippoliti G, Fronterrè A.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
    [No Abstract] [Full Text] [Related]

  • 18. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S, Legendre C, Noel LH, Bach JF, Kreis H, Chatenoud L.
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract] [Full Text] [Related]

  • 19. Basis for differing biological immunosuppressive potencies of monoclonal and polyclonal T cell antibodies.
    Sherburne CG, Condie RM, Onyekaba CO.
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1036-9. PubMed ID: 2523113
    [No Abstract] [Full Text] [Related]

  • 20. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ, Barry JM, Bennett WM, Munson JL, Meyer M, Henell K, Kimball J, Hubert B.
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.